News Snapshot:
An inactivated Covid-19 vaccine candidate developed by China has shown promising trial result as it is safe and generates an immune response, according to data from clinical trials published in The Journal of the American Medical Association this week. The results showed that the vaccine effectively induced neutralising antibodies in the volunteers and demonstrated good immunogenicity – the ability of a substance to trigger an immune response, reports Xinhua. The research paper provided an interim analysis of the phase-1 and phase-2 clinical trials of an inactivated COVID-19 vaccine developed by the Wuhan Institute of Biological Products under the China National...
